Global Kinetics Corporation (GKC), a digital health company involved in the management of Parkinson’s disease, said it received Notice of Allowance for a US patent application to protect the company’s lead product, the Personal KinetiGraph (PKG).
The product is known as Parkinson’s Kinetigraph outside of the US.
“The patent application pertains to the objective measurement of bradykinesia,” said Global Kinetics.
“Bradykinesia, or slowness of movement, is one of the most common symptoms, and a defining feature, of Parkinson’s disease.
“The capacity to continuously measure this movement symptom underpins the PKG system.”
GKC’s global head of business development and legal affairs Michelle Goldsmith said: “The allowance of this application supports GKC’s continued progress in the commercialization of our novel, U.S. FDA-cleared PKG system, which is being used to support the management of Parkinson’s disease in over 215 clinics in 16 countries around the world.
“We are aggressively pursuing clinical and commercial milestones that will ultimately enable us to make measurable change in the lives of people with Parkinson’s.”
The PKG system, developed by Professor Malcolm Horne and Dr. Rob Griffiths at Melbourne’s Howard Florey Institute and Monash University, involves a wrist-worn device to record body movements over several days as people go about their daily lives.
“GKC is currently conducting studies to establish the value of the PKG system in improving the entire advanced therapy pathway from more efficient referrals to better optimization on therapy,” added the company.